PriceTargets.com logo

NASDAQ:PDSB - PDS Biotechnology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.28
  • Forecasted Upside: 79.19 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$4.06 As of 02/26/2021 01:00 AM ET
▼ -0.39 (-8.76%)
1 month | 3 months | 12 months
Get New PDS Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PDSB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PDSB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.28
▲ +79.19% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for PDS Biotechnology in the last 3 months. The average price target is $7.28, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 79.19% upside from the last price of $4.06.
Buy
The current consensus among 4 polled investment analysts is to buy stock in PDS Biotechnology.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2020HC WainwrightUpgradeNeutral ➝ Buy$6.00Medium
i
Rating by J. Pantginis at HC Wainwright
10/6/2020Noble FinancialReiterated RatingBuy$6.60High
i
Rating by Cosme Ordonez at Noble Financial
7/28/2020Alliance Global PartnersBoost Price TargetBuy$4.00 ➝ $6.50Medium
i
7/8/2020Chardan CapitalReiterated RatingBuy$10.00Medium
i
Rating by Geulah Livshits at Chardan Capital
5/27/2020Alliance Global PartnersInitiated CoverageBuy$4.00Low
i
5/14/2020Noble FinancialReiterated RatingBuy$5.45Low
i
Rating by Cosme Ordonez at Noble Financial
5/13/2020HC WainwrightReiterated RatingHoldMedium
i
Rating by J. Pantginis at HC Wainwright
4/30/2020HC WainwrightReiterated RatingHoldHigh
i
Rating by J. Pantginis at HC Wainwright
4/21/2020Noble FinancialReiterated RatingBuy$5.45Low
i
3/30/2020HC WainwrightDowngradeBuy ➝ Neutral$7.00Medium
i
Rating by J. Pantginis at HC Wainwright
3/9/2020Noble FinancialInitiated CoverageOutperform$5.45High
i
12/23/2019Chardan CapitalReiterated RatingBuy$10.00High
i
Rating by Y. Livshits at Chardan Capital
11/5/2019HC WainwrightInitiated CoverageBuy$7.00 ➝ $7.00High
i
Rating by J. Pantginis at HC Wainwright
10/23/2019Chardan CapitalInitiated CoverageBuy$10.00High
i
Rating by Y. Livshits at Chardan Capital
(Data available from 2/27/2016 forward)
PDS Biotechnology logo
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial, a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104 (TRP2) for the treatment of melanoma. The company has a collaboration agreement with Merck & Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer; and an agreement with Farmacore Biotechnology for the development of Versamune-based vaccine to prevent COVID-19 infection. The company is based in Princeton, New Jersey.
Read More

Today's Range

Now: $4.06
$4.03
$4.52

50 Day Range

MA: $3.80
$2.39
$6.81

52 Week Range

Now: $4.06
$0.62
$7.30

Volume

419,065 shs

Average Volume

1,120,087 shs

Market Capitalization

$90.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.7

Frequently Asked Questions

What sell-side analysts currently cover shares of PDS Biotechnology?

The following Wall Street analysts have issued stock ratings on PDS Biotechnology in the last twelve months: Alliance Global Partners, Chardan Capital, HC Wainwright, Noble Financial, and Zacks Investment Research.
View the latest analyst ratings for PDSB.

What is the current price target for PDS Biotechnology?

4 Wall Street analysts have set twelve-month price targets for PDS Biotechnology in the last year. Their average twelve-month price target is $7.28, suggesting a possible upside of 79.2%. Chardan Capital has the highest price target set, predicting PDSB will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for PDS Biotechnology in the next year.
View the latest price targets for PDSB.

What is the current consensus analyst rating for PDS Biotechnology?

PDS Biotechnology currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PDSB will outperform the market and that investors should add to their positions of PDS Biotechnology.
View the latest ratings for PDSB.

What other companies compete with PDS Biotechnology?

Other companies that are similar to PDS Biotechnology include Nabriva Therapeutics, ANI Pharmaceuticals, Oncorus, Aeglea BioTherapeutics, Verrica Pharmaceuticals, Sesen Bio, VistaGen Therapeutics, Fortress Biotech, Paratek Pharmaceuticals, Trevena, CymaBay Therapeutics, Immunic, Nature's Sunshine Products, Arbutus Biopharma and Ampio Pharmaceuticals.

How do I contact PDS Biotechnology's investor relations team?

PDS Biotechnology's physical mailing address is 25B Vreeland Road, Florham Park NJ, 07932. The company's listed phone number is 800-208-3343 and its investor relations email address is [email protected] The official website for PDS Biotechnology is www.pdsbiotech.com.